La Jolla, Calif.-based MediciNova announced that the company’s Phase II clinical trial of ibudilast (MN-166) failed to meet its primary endpoint for methamphetamine dependence.
Shares of Edge Therapeutics were in a free fall following the company’s decision to discontinue development of a late-stage treatment for adults with aneurysmal subarachnoid hemorrhage.
A Novartis leukemia drug continues to be the subject of a handful of lawsuits filed by plaintiffs due to concerns over atherosclerosis-related conditions.
FDA Orphan Drug Designation Granted for MaxiNovel Pharmaceuticals’ MAX-40279 for the Treatment of Acute Myeloid Leukemia
MaxiNovel Pharmaceuticals, Inc. Announces FDA Orphan Drug Designation for MAX-40279 for the Treatment of Acute Myeloid Leukemia (AML) GUANGZHOU, China–(BUSINESS WIRE)–MaxiNovel Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (“FDA”) has granted MaxiNovel Orphan Drug Designation for MAX-40279 in the treatment of Acute Myeloid Leukemia (AML). AML is the most […]
Impax Laboratories Inc. agreed to pay $20 million to consumers and insurers to resolve claims that the drugmaker entered an anticompetitive deal to delay launching a generic, cheaper version of the acne medication Solodyn.
Dr. Reddy’s Laboratories Ltd. announced a change in the makeup of the company’s senior leadership team.
A federal judge overturned a U.S. jury’s verdict that required Teva Pharmaceutical Industries Ltd. to pay GlaxoSmithKline Plc more than $235 million for infringing a patent covering its blood pressure drug Coreg.
The U.S. Food and Drug Administration approved Mylan NV’s Symfi (efavirnenz, lamivudine and tenofovir disoproxil fumarate) for adult and pediatric HIV-1 patients who weigh at least 40 kilograms.
Celgene Corp. and bluebird bio Inc. inked a development and promotion deal for bb2121, bluebird’s B-cell maturation antigen CAR-T therapy for relapsed/refractory multiple myeloma.